CRISPR Therapeutics (CRSP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.94
- Estimate
- -$1.18
- Surprise
- +20.6%
- Revenue (period 2026-06-30)
- $10.2M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
CRISPR Therapeutics (CRSP) reported a narrower loss than forecast — adjusted EPS of -$0.94 against the -$1.18 estimate (a 20.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRSP Sell at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +20.6% surprise compares with a -0.8% four-quarter average. Next scheduled report: 2027-02-11.
What argues against it
- Quality below floor (1.8 < 4.0)
- Value-trap signals (3/5): Revenue declining (-42.9% YoY), Margin compression (op margin -4043.8%), Negative free cash flow
- Momentum score 4.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $52.03
- Price target
- $77.07
- Stop
- $48.39
- Upside to target
- +48.1%
- Reward-to-risk
- 5.3:1
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
CRSP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.83B
- P/E (fwd)
- -13.9
- 52-week range
- $44.12–$63.45
- Off 52-week high
- 18.0%
- RSI (14)
- 52
- Volume vs avg
- 0.50×
- Score today
- 5.0/10